These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 16524799)
1. Is there a therapeutic role for Agmatine? Euler DE Anadolu Kardiyol Derg; 2006 Mar; 6(1):39-40. PubMed ID: 16524799 [No Abstract] [Full Text] [Related]
2. Vascular rho kinases and their potential therapeutic applications. Budzyn K; Sobey CG Curr Opin Drug Discov Devel; 2007 Sep; 10(5):590-6. PubMed ID: 17786858 [TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Touyz RM; Schiffrin EL Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin II-type 2 receptor: emerging target for cardiovascular protection. Schmieder RE Am J Hypertens; 2010 Mar; 23(3):220. PubMed ID: 20154649 [No Abstract] [Full Text] [Related]
5. The potential use of the pregnane X receptor in cardiovascular therapy. Swales KE; Bishop-Bailey D Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1079-82. PubMed ID: 23098141 [No Abstract] [Full Text] [Related]
6. How We Learned to Say NO. Vanhoutte PM Arterioscler Thromb Vasc Biol; 2009 Aug; 29(8):1156-60. PubMed ID: 19605779 [No Abstract] [Full Text] [Related]
7. [The function of the vascular wall and drug action]. Chekman IS; Kazak LI Lik Sprava; 1993; (10-12):3-8. PubMed ID: 8030302 [No Abstract] [Full Text] [Related]
8. L-NAME pre-treatment partially inhibits the agmatine-evoked depression of the electrically induced twitch contraction of isolated rat vas deferens. Garcez-do-Carmo L; Santos WC Life Sci; 2006 Jul; 79(9):854-60. PubMed ID: 16564552 [TBL] [Abstract][Full Text] [Related]
9. The 'PAI-1 paradox' in vascular remodeling. Diebold I; Kraicun D; Bonello S; Görlach A Thromb Haemost; 2008 Dec; 100(6):984-91. PubMed ID: 19132221 [TBL] [Abstract][Full Text] [Related]
10. [The basis for treatment of cardiovascular diseases: cellular and molecular mechanisms of Crataegus extract]. Brixius K; Willms S; Schwinger RH Pharm Unserer Zeit; 2005; 34(1):48-51. PubMed ID: 15700795 [No Abstract] [Full Text] [Related]
11. Activation of protein kinase B/Akt and endothelial nitric oxide synthase mediates agmatine-induced endothelium-dependent relaxation. Santhanam AV; Viswanathan S; Dikshit M Eur J Pharmacol; 2007 Oct; 572(2-3):189-96. PubMed ID: 17640632 [TBL] [Abstract][Full Text] [Related]
13. Potential uses of a new class of low-molecular-weight heparins in cardiovascular indications. Cohen M; Blaber R Semin Thromb Hemost; 1996; 22 Suppl 2():25-7. PubMed ID: 8946616 [No Abstract] [Full Text] [Related]
14. Development of Rho-kinase inhibitors for cardiovascular medicine. Shimokawa H; Rashid M Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681 [TBL] [Abstract][Full Text] [Related]
17. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Hirano K Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):27-36. PubMed ID: 17095716 [TBL] [Abstract][Full Text] [Related]
18. The effects of interleukin-6 on the contraction and relaxation responses of the cavernous smooth muscle from rats. Myung SC; Han JH; Song KK; Kang GH; Lee SY; Kim TH; Lee MY; Kim HW; Kim SC Eur J Pharmacol; 2008 Jul; 589(1-3):228-32. PubMed ID: 18555215 [TBL] [Abstract][Full Text] [Related]
19. Control of the vasculature: pharmacological targets in vascular disease. Sobrevia L Curr Vasc Pharmacol; 2009 Oct; 7(4):423-5. PubMed ID: 19863478 [No Abstract] [Full Text] [Related]
20. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Brinkmann V; Baumruker T Curr Opin Pharmacol; 2006 Jun; 6(3):244-50. PubMed ID: 16563863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]